135 related articles for article (PubMed ID: 36377242)
1. A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 Years.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Hofmeister L; Sood N
Clin Appl Thromb Hemost; 2022; 28():10760296221133083. PubMed ID: 36377242
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
[No Abstract] [Full Text] [Related]
4. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
[TBL] [Abstract][Full Text] [Related]
5. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
Costa OS; O'Donnell B; Vardar B; Abdelgawwad K; Brescia CW; Sood N; Coleman CI
Curr Med Res Opin; 2021 Sep; 37(9):1493-1500. PubMed ID: 34166150
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
8. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
[TBL] [Abstract][Full Text] [Related]
12. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Miao B; Alberts MJ; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2019 Oct; 48(3):366-372. PubMed ID: 31228038
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
16. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.
Baker WL; Beyer-Westendorf J; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
Diabetes Obes Metab; 2019 Sep; 21(9):2107-2114. PubMed ID: 31099460
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
[TBL] [Abstract][Full Text] [Related]
20. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
